A(nother) RAF mutation in LCH.

Abstract excerpt

In this issue of Blood, Nelson et al describe a novel somatic ARAF mutation in a child with Langerhans cell histiocytosis (LCH) and demonstrate that the encoded protein has strong gain-of-function properties. Importantly, this mutant A-Raf molecule is sensitive to inhibition by vemurafenib, a potent and selective Raf kinase inhibitor that is Food and Drug Administration (FDA)-approved for the treatment of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Histiocytosis, Langerhans-Cell
• Share to Mutation